Objective: To compare plasma etonogestrel concentrations sampled from the contralateral- versus ipsilateral-to-implant arm.
Study Design: Sub-analysis of a cross-sectional study in Botswana in 33 participants who provided contralateral and ipsilateral blood samples.
Results: Plasma etonogestrel concentrations in contralateral and ipsilateral specimens were highly correlated (correlation coefficient = 0.99; p < 0.0001). Bland-Altman analysis of agreement showed that etonogestrel levels were on average 5.9 pg/mL higher (2.1%) in ipsilateral compared to contralateral specimens (95% confidence interval: -4.1, 15.9 pg/mL).
Conclusions: We found no meaningful differences in plasma etonogestrel concentrations between samples taken from the contralateral- versus ipsilateral-to-implant arm.
Implications: Our data suggest that etonogestrel plasma concentrations are unlikely to be meaningfully different between samples drawn from the ipsilateral- versus the contralateral-to-implant arms in etonogestrel contraceptive implant users.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232040 | PMC |
| http://dx.doi.org/10.1016/j.contraception.2020.08.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of etonogestrel bioanalytical assay results in plasma and serum within and across laboratories.
Contraception
February 2025
Antiviral Pharmacology Laboratory, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA. Electronic address:
Article Synopsis
- This study aimed to compare how different laboratories measure etonogestrel, a contraceptive hormone, focusing on accuracy and precision across six labs (five academic and one commercial).
- In tests with prepared serum and plasma samples, four labs achieved accurate results within ±15% of expected concentrations, while high precision was demonstrated, with minimal variation across results.
- However, while individual labs generally correlated well with a reference lab for serum samples, some showed biases resulting in consistently higher or lower readings, highlighting variability in etonogestrel measurement methods across different facilities.
Next-Generation Contraceptive Intravaginal Ring: Comparison of Etonogestrel and Ethinyl Estradiol In Vitro and In Vivo Release from 3D-Printed Intravaginal Ring and NuvaRing.
Pharmaceutics
August 2024
Division of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Intravaginal rings (IVRs) represent a well-established, woman-controlled and sustained vaginal drug delivery system suitable for a wide range of applications. Here, we sought to investigate the differences in etonogestrel (ENG) and ethinyl estradiol (EE) release from a 3D-printed IVR utilizing continuous liquid interface production (CLIP™) (referred to as CLIP for low drug loading and CLIP IVRs for high drug loading) and NuvaRing, a commercially available injection molded IVR. We conducted in vitro release studies in simulated vaginal fluid to compare the release of ENG and EE from CLIP IVRs and NuvaRing.
View Article and Find Full Text PDFA randomized trial of double vs single-dose etonogestrel implant to overcome the interaction with efavirenz-based antiretroviral therapy.
Am J Obstet Gynecol
August 2024
Department of Pharmacy Practice and Science, University of Nebraska Medical Center, Omaha, NE; Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE.
Background: Concomitant use of efavirenz-based antiretroviral therapy and a standard-dose etonogestrel contraceptive implant led to 82% lower etonogestrel exposure when compared with women who do not receive antiretroviral therapy. The clinical impact of this reduced exposure is supported by retrospective cohort evaluations that demonstrated higher rates of unintended pregnancies when contraceptive implants were combined with efavirenz. We hypothesized that placement of 2 etonogestrel implants in those taking efavirenz-based antiretroviral therapy could increase etonogestrel exposure and improve measures of contraceptive efficacy.
View Article and Find Full Text PDFPharmacokinetic Study of Islatravir and Etonogestrel Implants in Macaques.
Pharmaceutics
November 2023
RTI International, Durham, NC 27709, USA.
The prevention of HIV and unintended pregnancies is a public health priority. Multi-purpose prevention technologies capable of long-acting HIV and pregnancy prevention are desirable for women. Here, we utilized a preclinical macaque model to evaluate the pharmacokinetics of biodegradable ε-polycaprolactone implants delivering the antiretroviral islatravir (ISL) and the contraceptive etonogestrel (ENG).
View Article and Find Full Text PDFLong-acting injectable multipurpose prevention technology for prevention of HIV and unplanned pregnancy.
J Control Release
November 2023
Division of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Joint Department of Biomedical Engineering, North Carolina State University and The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address:
Article Synopsis
- Only condoms effectively prevent both HIV and unplanned pregnancies, but user acceptability and partner cooperation can reduce their effectiveness.
- Researchers developed a novel injectable implant that combines antiretroviral drugs (like dolutegravir and cabotegravir) with hormonal contraceptives (etonogestrel and medroxyprogesterone acetate) for multipurpose prevention.
- Studies in mice showed that this implant is safe and well-tolerated, maintaining effective drug concentrations for 90 days after administration, indicating its potential as an effective preventive method.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!